Literature DB >> 16989261

Mass vaccination: when and why.

D L Heymann1, R B Aylward.   

Abstract

With increased demand for smallpox vaccination during the nineteenth century, vaccination days--early mass vaccination campaigns--were conducted over time-limited periods to rapidly and efficiently protect maximum numbers of susceptible persons. Two centuries later, the challenge to rapidly and efficiently protect populations by mass vaccintion continues, despite the strengthening of routine immunization services in many countries through the Expanded Programme on Immunization strategies and GAVI support. Perhaps the most widely accepted reason for mass vaccination is to rapidly increase population (herd) immunity in the setting of an existing or potential outbreak, thereby limiting the morbidity and mortality that might result, especially when there has been no routine vaccination, or because populations have been displaced and routine immunization services disrupted. A second important use of mass vaccination is to accelerate disease control to rapidly increase coverage with a new vaccine at the time of its introduction into routine immunization programmes, and to attain the herd immunity levels required to meet international targets for eradication and mortality reduction. In the twenty-first century, mass vaccination and routine immunization remain a necessary alliance for attaining both national and international goals in the control of vaccine preventable disease.

Entities:  

Mesh:

Year:  2006        PMID: 16989261     DOI: 10.1007/3-540-36583-4_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  12 in total

1.  Group 1 Vaccinia virus zoonotic outbreak in Maranhao State, Brazil.

Authors:  Danilo Bretas Oliveira; Felipe Lopes Assis; Paulo Cesar Peregrino Ferreira; Cláudio Antônio Bonjardim; Giliane de Souza Trindade; Erna Geessien Kroon; Jônatas Santos Abrahão
Journal:  Am J Trop Med Hyg       Date:  2013-10-28       Impact factor: 2.345

Review 2.  Prioritization of pandemic influenza vaccine: rationale and strategy for decision making.

Authors:  Benjamin Schwartz; Walter A Orenstein
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

3.  Short-tailed stx phages exploit the conserved YaeT protein to disseminate Shiga toxin genes among enterobacteria.

Authors:  Darren L Smith; Chloë E James; Martin J Sergeant; Yan Yaxian; Jon R Saunders; Alan J McCarthy; Heather E Allison
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490

4.  Factors associated with the uptake of seasonal influenza vaccination in older and younger adults: a large, population-based survey in Beijing, China.

Authors:  Shuangsheng Wu; Jianting Su; Peng Yang; Haiyan Zhang; Hongjun Li; Yanhui Chu; Weiyu Hua; Chao Li; Yaqing Tang; Quanyi Wang
Journal:  BMJ Open       Date:  2017-09-25       Impact factor: 2.692

5.  The comprehensive 'Communicate to Vaccinate' taxonomy of communication interventions for childhood vaccination in routine and campaign contexts.

Authors:  Jessica Kaufman; Heather Ames; Xavier Bosch-Capblanch; Yuri Cartier; Julie Cliff; Claire Glenton; Simon Lewin; Artur Manuel Muloliwa; Afiong Oku; Angela Oyo-Ita; Gabriel Rada; Sophie Hill
Journal:  BMC Public Health       Date:  2017-05-10       Impact factor: 3.295

6.  One more piece in the VACV ecological puzzle: could peridomestic rodents be the link between wildlife and bovine vaccinia outbreaks in Brazil?

Authors:  Jônatas S Abrahão; Maria Isabel M Guedes; Giliane S Trindade; Flávio G Fonseca; Rafael K Campos; Bruno F Mota; Zélia I P Lobato; André T Silva-Fernandes; Gisele O L Rodrigues; Larissa S Lima; Paulo C P Ferreira; Cláudio A Bonjardim; Erna G Kroon
Journal:  PLoS One       Date:  2009-10-19       Impact factor: 3.240

7.  Characterization of a new Vaccinia virus isolate reveals the C23L gene as a putative genetic marker for autochthonous Group 1 Brazilian Vaccinia virus.

Authors:  Felipe L Assis; Gabriel M F Almeida; Danilo B Oliveira; Ana P M Franco-Luiz; Rafael K Campos; Maria I M Guedes; Flávio G Fonseca; Giliane S Trindade; Betânia P Drumond; Erna G Kroon; Jônatas S Abrahão
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

8.  Comparison of school based and supplemental vaccination strategies in the delivery of vaccines to 5-19 year olds in Africa - a systematic review.

Authors:  Eposi C Haddison; Leila H Abdullahi; Rudzani Muloiwa; Gregory D Hussey; Benjamin M Kagina
Journal:  F1000Res       Date:  2017-10-13

9.  Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects.

Authors:  Corey M Peak; Amanda L Reilly; Andrew S Azman; Caroline O Buckee
Journal:  PLoS Negl Trop Dis       Date:  2018-02-28

10.  The case for ring vaccinations with special consideration of oral cholera vaccines.

Authors:  Jacqueline Deen; Lorenz von Seidlein
Journal:  Hum Vaccin Immunother       Date:  2018-05-11       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.